Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response

[1]  W. Gillanders,et al.  Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma , 2017, Gut.

[2]  T. McGaha,et al.  Type I Interferon in Chronic Virus Infection and Cancer. , 2017, Trends in immunology.

[3]  J. Huse,et al.  Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas , 2017, Oncogene.

[4]  Emily A Foley,et al.  Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents , 2017, Cell reports.

[5]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[6]  S. Lang,et al.  The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils , 2016, Front. Immunol..

[7]  D. Quail,et al.  Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies , 2016, Clinical Cancer Research.

[8]  C. Ries,et al.  Macrophage Susceptibility to Emactuzumab (RG7155) Treatment , 2016, Molecular Cancer Therapeutics.

[9]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[10]  Eric C. Holland,et al.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas , 2016, Science.

[11]  P. Hertzog,et al.  Optimizing mouse models for precision cancer prevention , 2016, Nature Reviews Cancer.

[12]  R. Bernards,et al.  Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer , 2016, Scientific Reports.

[13]  S. Smale,et al.  Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence , 2016, PLoS pathogens.

[14]  Y. Miao,et al.  Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. , 2016, Cancer biomarkers : section A of Disease markers.

[15]  K. D. de Visser,et al.  Purification of Immune Cell Populations from Freshly Isolated Murine Tumors and Organs by Consecutive Magnetic Cell Sorting and Multi-parameter Flow Cytometry-Based Sorting. , 2016, Methods in molecular biology.

[16]  D. Golenbock,et al.  Type I Interferon Transcriptional Signature in Neutrophils and Low-Density Granulocytes Are Associated with Tissue Damage in Malaria. , 2015, Cell reports.

[17]  L. Spinelli,et al.  BubbleGUM: automatic extraction of phenotype molecular signatures and comprehensive visualization of multiple Gene Set Enrichment Analyses , 2015, BMC Genomics.

[18]  L. Zitvogel,et al.  Autocrine signaling of type 1 interferons in successful anticancer chemotherapy , 2015, Oncoimmunology.

[19]  F. Balkwill,et al.  Inflammation and cancer: advances and new agents , 2015, Nature Reviews Clinical Oncology.

[20]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[21]  J. Blay,et al.  Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors. , 2015 .

[22]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[23]  S. Coffelt,et al.  Immune-mediated mechanisms influencing the efficacy of anticancer therapies. , 2015, Trends in immunology.

[24]  Z. Ballatore,et al.  Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients , 2015, BMC Cancer.

[25]  S. Chin,et al.  Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms , 2015, Molecular oncology.

[26]  J. Jonkers,et al.  IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis , 2015, Nature.

[27]  H. Kohrt,et al.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications , 2015, Oncoimmunology.

[28]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[29]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[30]  Marijn T. M. van Jaarsveld,et al.  Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response , 2014, Nature Communications.

[31]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[32]  A. Alimonti,et al.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer , 2014, Nature.

[33]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[34]  M. Dugo,et al.  Subtype‐dependent prognostic relevance of an interferon‐induced pathway metagene in node‐negative breast cancer , 2014, Molecular oncology.

[35]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[36]  R. Wong,et al.  Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase , 2014, Oncogene.

[37]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[38]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[39]  A. Snijders,et al.  An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival , 2014, Oncotarget.

[40]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[41]  D. Berry,et al.  The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context , 2013, PloS one.

[42]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[43]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[44]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[45]  J. Jonkers,et al.  A preclinical mouse model of invasive lobular breast cancer metastasis. , 2013, Cancer research.

[46]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[47]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[48]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[49]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[50]  J. Jonkers,et al.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system , 2012, Nature Medicine.

[51]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[52]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[53]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[54]  C. Sousa.  Faculty Opinions recommendation of Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. , 2011 .

[55]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[56]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[57]  Gary D. Bader,et al.  WordCloud: a Cytoscape plugin to create a visual semantic summary of networks , 2011, Source Code for Biology and Medicine.

[58]  R. Weichselbaum,et al.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.

[59]  V. Baracos,et al.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer , 2011, British Journal of Cancer.

[60]  L. Bracci,et al.  Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. , 2011, Cancer research.

[61]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[62]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[63]  Albert Koong,et al.  Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.

[64]  W. Born,et al.  IL‐17‐producing γδ T cells , 2009, European Journal of Immunology.

[65]  E. Abdalla,et al.  Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy , 2009, Annals of Surgical Oncology.

[66]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[67]  E. Bradley,et al.  Novel Pro-survival Functions of the Kruppel-like Transcription Factor Egr2 in Promotion of Macrophage Colony-stimulating Factor-mediated Osteoclast Survival Downstream of the MEK/ERK Pathway* , 2008, Journal of Biological Chemistry.

[68]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[69]  Jos Jonkers,et al.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. , 2006, Cancer cell.

[70]  E. Stanley,et al.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.

[71]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Martin Kuiper,et al.  BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..

[73]  S. Aaronson,et al.  Implications for Cancer Therapy , 2003 .